TF and cancer: A different approach to carbohydrate-based galectin inhibitors was proposed by Glinsky et al., who showed that a synthetic β-galactoside-containing disaccharide-amino acid conjugate, the glycoamine lactulose-l-leucine (Lac-l-Leu, 19, Table 3), binds and inhibits Gal-3 by mimicking cancer-associated Tf antigen (Figure 1).